Slide 1: Full Year and Q4 2022 Results
Full Year and Q4 2022 Results Conference call and webcast for investors and analysts 9 February 2023
Slide 2: Forward-looking statements
Forward-looking statements AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expe
Slide 3: Conference call agenda
Full Year and Q4 2022 results Conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Oncology Dave Fredrickson Susan Galbraith EVP, Oncology Business EVP, Oncology R&D BioPharmaceuticals Ruud Dobber Mene Pangalos EVP,
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 5: Strong FY 2022 – well positioned to deliver future growth
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Strong FY 2022 – well positioned to deliver future growth Delivered on our upgraded FY 2022 guidance Broad-based, diverse source of business Total Revenue Core EPS FY 2022 | % Total Revenue by therapy
Slide 6: Exciting pipeline progress in FY 2022
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Exciting pipeline progress in FY 2022 – rapidly advancing high-potential new medicines Initiating >30 Phase III trials in 2023 12 8 select examples: including 10 potential blockbusters blockbuster medi
Slide 7: Investing to unlock next waves of innovation
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Investing to unlock next waves of innovation Committed to science-led innovation investment in new platforms and technologies 156 high-impact journal manuscripts • Small molecules e.g., PROTACS, nanopa
Slide 8: Industry-leading outlook to 2025 and beyond
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Industry-leading outlook to 2025 and beyond Ambition to launch at least 15 NMEs by 2030 2023 mid-to-long term ambition Strong underlying revenue Total Revenue ambition2: and profitability growth Low do
Slide 9: Financial Results
Financial Results Aradhana Sarin CHIEF FINANCIAL OFFICER
Slide 10: FY and Q4 2022 – Core profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks FY and Q4 2022 – Core profit and loss Continued operating leverage FY 2022 CER change % total Q4 2022 CER change % total $m % revenue $m % revenue Total Revenue 44,351 25 100 11,207 1 100 - Product Sal
Slide 11: FY and Q4 2022 – Reported profit and loss
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks FY and Q4 2022 – Reported profit and loss Continued strong top-line growth FY 2022 CER change % total Q4 2022 CER change % total $m % revenue $m % revenue Total Revenue 44,351 25 100 11,207 1 100 - Pro
Slide 12: FY 2022 – Net Debt and Cash Flow
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks FY 2022 – Net Debt and Cash Flow Strong cash flow from operations delivered improved cash flow in 2022 Net Debt bridge • Strong investment grade credit rating $bn • Reinvestment in the business • Value
Slide 13: FY 2023 guidance (CER)
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks FY 2023 guidance (CER) Strong underlying business drives growth well ahead of declines in COVID-19 medicines Other elements of 2023 guidance Total Revenue • Total Revenue from COVID-19 medicines Exclud
Slide 14: Oncology
Oncology Dave Fredrickson ONCOLOGY BUSINESS Susan Galbraith ONCOLOGY R&D
Slide 15: Oncology: FY 2022
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: FY 2022 Broad, differentiated portfolio drives strong commercial performance Oncology Q4 2022: key dynamics FY 2022 $15.5bn, +20% at CER 4,500 4,000 • Double-digit Product Sales growth across
Slide 16: Oncology: near-term commercial performance drivers
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: near-term commercial performance drivers Continuing launch execution, expanding geographic presence, establishing new SoC FY 2022: $5.4bn, +15% at CER FY 2022: $2.8bn, +21% at CER FY 2022 PS:
Slide 17: Oncology: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: R&D highlights Data-rich presence at SABCS, new adjuvant trial for camizestrant (ngSERD) SABCS: capivasertib SABCS: camizestrant first-in-class AKT addressing key unmet need increased confide
Slide 18: Oncology: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: R&D highlights ASH showcases Calquence best-in-class safety and efficacy, first data for AZD0486 ASH: Calquence ASH: AZD0486 long-term follow-up data supports continued use of Calquence first
Slide 19: Oncology: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: R&D highlights Dato-DXd: Phase III combination trials address unmet need in 1st-line IO-sensitive NSCLC NEW Dato-DXd AVANZAR Phase III Dato-DXd TROPION-Lung07 Phase III Dato-DXd + • PD-L1 < 5
Slide 20: Oncology: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Oncology: R&D highlights Novel bispecific programmes advance with new pivotal trials, including in NSCLC volrustomig rilvegostomig PD-1/CTLA-4 bispecific PD-1/TIGIT bispecific • Accelerated development
Slide 21: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BIOPHARMACEUTICALS BUSINESS Mene Pangalos BIOPHARMACEUTICALS R&D
Slide 22: BioPharmaceuticals: FY 2022
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals: FY 2022 Total Revenue $20bn, +11% at CER, driven by Farxiga strength and R&I launches CVRM R&I V&I FY 2022 $9.2bn, +19% at CER FY 2022 $6.0bn, +3% at CER FY 2022 $4.8bn, +8% at CER
Slide 23: BioPharmaceuticals: near-term commercial drivers
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals: near-term commercial drivers Capitalising on pipeline advances, expanding patient reach and driving practice change Executing launch in major markets Competitive launch in expanding
Slide 24: BioPharmaceuticals: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals: R&D highlights Strengthening our CVRM portfolio with planned new late-stage trials and NMEs Cardiovascular Heart Failure Kidney disease Metabolism NEW zibotentan (ETA) NEW balcinren
Slide 25: BioPharmaceuticals: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals: R&D highlights Combinations trials to sustain revenue post Farxiga LoE balcinrenone with Farxiga zibotentan with Farxiga baxdrostat with Farxiga balcinrenone zibotentan baxdrostat c
Slide 26: BioPharmaceuticals: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks BioPharmaceuticals: R&D highlights Pipeline progression in R&I and V&I tozorakimab (IL-33) Saphnelo % CI (0.10–1.12) expanding into additional autoimmune diseases Phase III trial | ARF in patients with
Slide 27: Rare Disease
Rare Disease Marc Dunoyer CHIEF EXECUTIVE OFFICER, ALEXION
Slide 28: Rare Disease: FY 2022
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease: FY 2022 Strong neurology growth across C5, continued strength beyond complement Rare Disease Q4 2022: key dynamics FY 2022 $7.1bn, +10% pro forma1 at CER 2,000 Durable C5 Franchise growth
Slide 29: Rare Disease: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease: R&D highlights PNH well-served by C5 franchise with danicopan add-on PNH patient population C5 will remain SoC in PNH addressing spectrum of patient need addresses IVH, underlying cause o
Slide 30: Rare Disease: R&D highlights
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks Rare Disease: R&D highlights Accelerating innovation across our pipeline Ultomiris CSA-AKI ALXN1850 HPP initiating Phase III in 2023 initiating Phase III in 2023 High incidence of acute kidney injury a
Slide 31: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot CHIEF EXECUTIVE OFFICER
Slide 32: AstraZeneca
CEO Opening Remarks Financial Results Oncology BioPharmaceuticals Rare Disease CEO Closing Remarks AstraZeneca Accelerating pipeline momentum in 2023 and disciplined investment to fuel industry-leading growth Pipeline advances in 2023 Sustainable, long-term growth with 18 Phase III read-outs anticip
Slide 33: FY 2022 Question & Answer Session
FY 2022 Question & Answer Session Pascal Soriot Aradhana Sarin Marc Dunoyer E X E CUTI V E D I R E CTO R & E XE CUTI VE DI RE CTOR & CHI E F E XE CUTI VE OFFI CE R, CHI E F E X E CUTI VE OFFI CE R CHI E F FI NANCI AL OFFI CE R AL E XI ON Susan Galbraith Dave Fredrickson Mene Pangalos E X E CUTI V E
Slide 34: Appendix
Appendix ▪ Pipeline Highlights since YTD2022 results ▪ ESG & Corporate Sustainability ▪ Oncology landscapes: breast and lung ▪ Emerging Markets ▪ Key Performance by Therapy Area
Slide 35: Delivering on science-led innovation
A PPE N D I X | Pipeline Highlights Delivering on science-led innovation Selected key pipeline highlights since YTD2022 results Oncology BioPharmaceuticals Rare Disease 3 Fast Track Designations (US): 16 regulatory approvals in major markets, including: capivasertib Imfinzi +/- Imjudo (US, JP) Enher
Slide 36: ESG & Corporate Sustainability
A PPE N D I X | ESG & Corporate Sustainability AstraZeneca Maintained leading rating since 2014 AstraZeneca vs. industry average AA SCORECARD by KEY ATTRIBUTE HIGHLIGHTS ESG RATINGS as of January 2023 Access to Healthcare Robust initiatives to capitalize on access to healthcare opportunities AstraZe
Slide 37: Emerging Markets: FY 2022
A PPE N D I X | Emerging Markets Emerging Markets: FY 2022 Total Revenue $11.8bn, +1% including Vaxzevria1 Emerging Markets, +16% ex Vaxzevria EM Total Revenue FY highlights: 4,000 3,500 ▪ Oncology: Tagrisso +22%, Lynparza +31% Q4 2022 | % EM Total Revenues 3,000 2,500 ▪ CVRM: Farxiga +47% Total Rev
Slide 38: Oncology: Tagrisso, Imfinzi/Imjudo
A PPE N D I X | FY 2022 Product Performance Oncology Tagrisso Imfinzi/Imjudo 15% growth to $5,444m 21% growth to $2,784m 1,600 800 1,400 700 1,200 600 Total Revenue ($m) Total Revenue ($m) 1,000 500 800 400 600 300 400 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 2021 20
Slide 39: Oncology: Lynparza
A PPE N D I X | FY 2022 Product Performance Oncology Lynparza Lynparza 18% growth to $2,638m (excludes Collaboration Revenue) Collaboration Revenue: $3.8bn recorded, $3.9bn future potential 800 1000 700 800 600 Total Revenue ($m) Collaboration Revenue ($m) 500 600 400 400 300 200 200 100 0 - Q1 Q2 Q
Slide 40: Oncology: Calquence, Enhertu
A PPE N D I X | FY 2022 Product Performance Oncology Calquence Enhertu 69% growth to $2,057m >2x growth to $602m 700 250 600 200 500 Total Revenue ($m) Total Revenue ($m) 150 400 300 100 200 50 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 2021 2022 EM 2 5 5 8 7 8 12 17 EM 1 3 4
Slide 41: BioPharmaceuticals: Cardiovascular, Renal & Metabolism
A PPE N D I X | FY 2022 Product Performance BioPharmaceuticals: Cardiovascular, Renal & Metabolism Farxiga Brilinta Lokelma 56% growth to $4,386m 4% decrease to $1,358m 75% growth to $289m 1,400 400 90 350 80 1,200 70 300 1,000 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 60 250 800 50 2
Slide 42: BioPharmaceuticals: Respiratory & Immunology
A PPE N D I X | FY 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Fasenra 2% decrease to $2,538m 15% growth to $1,396m 800 450 700 400 350 600 Total Revenue ($m) Total Revenue ($m) 300 500 250 400 200 300 150 200 100 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Slide 43: BioPharmaceuticals: Respiratory & Immunology
A PPE N D I X | FY 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Breztri Pulmicort >2x growth to $398m 31% decline to $645m 140 350 120 300 100 250 Total Revenue ($m) Total Revenue ($m) 80 200 60 150 40 100 20 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2021 2022 2
Slide 44: Rare Disease
A PPE N D I X | FY 2022 Product Performance Rare Disease Soliris Ultomiris Strensiq 5% decrease to $3,762m 42% growth to $1,965m 18% growth to $958m 700 1,200 300 600 1,000 250 500 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 800 200 400 600 300 150 400 200 100 200 100 50 0 0 Q1 Q2 Q3 Q4
Slide 45: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis